Suppr超能文献

通过将亲和配体直接固定在纤维素上,从植物中纯化抗体。

Purification of plant-derived antibodies through direct immobilization of affinity ligands on cellulose.

机构信息

School of Environmental Sciences, University of Guelph, Ontario, Canada.

出版信息

J Agric Food Chem. 2010 Mar 24;58(6):3451-9. doi: 10.1021/jf9040657.

Abstract

Plants possess enormous potential as factories for the large scale production of therapeutic reagents such as recombinant proteins and antibodies. A major factor limiting commercial advances of plant-derived pharmaceuticals is the cost and inefficiency of purification. As a model system, we have developed a simple yet robust method for immobilizing affinity capture ligands onto solid supports by interfacing the secreted expression and coupling of a chimeric fusion protein in Pichia pastoris to microcrystalline cellulose in a single step. The fusion protein, which consisted of antibody-binding proteins L and G fused to a cellulose-binding domain (LG-CBD), was tethered directly onto cellulose resins added to P. pastoris cultures and subsequently used for antibody purification. Both the antibody-binding protein L and protein G domains were functional, as demonstrated by the ability of cellulose-immobilized LG-CBD to purify both a scFv antibody fragment from yeast and a human IgG1 monoclonal antibody from transgenic tobacco. Furthermore, combining two P. pastoris strains expressing LG-CBD and scFv with CP-102 cellulose in a single culture allowed for easy recovery of biologically active scFv. Direct immobilization of affinity purification ligands, such as LG-CBD, onto inexpensive support matrices such as cellulose is an effective method for the generation of functional, single-use antibody purification reagents. Straightforward preparation of purification reagents will help make antibody purification from genetically modified crop plants feasible and address one of the major bottlenecks facing commercialization of plant-derived pharmaceuticals.

摘要

植物具有作为大规模生产治疗试剂(如重组蛋白和抗体)的工厂的巨大潜力。限制植物来源药物商业进展的一个主要因素是成本和纯化效率低。作为一个模型系统,我们开发了一种简单而强大的方法,通过将毕赤酵母中的分泌表达和嵌合融合蛋白的偶联与微晶纤维素在一步界面连接,将亲和捕获配体固定在固体载体上。融合蛋白由抗体结合蛋白 L 和 G 与纤维素结合结构域(LG-CBD)融合而成,直接固定在添加到毕赤酵母培养物中的纤维素树脂上,随后用于抗体纯化。抗体结合蛋白 L 和蛋白 G 结构域均具有功能,这可以通过纤维素固定化 LG-CBD 从酵母中纯化 scFv 抗体片段和从转基因烟草中纯化人 IgG1 单克隆抗体来证明。此外,将表达 LG-CBD 和 scFv 的两种毕赤酵母菌株与 CP-102 纤维素在单一培养物中组合使用,可轻松回收具有生物活性的 scFv。将亲和纯化配体(如 LG-CBD)直接固定在廉价的支持基质(如纤维素)上是一种有效的方法,可生成功能性、一次性使用的抗体纯化试剂。简单制备纯化试剂将有助于使从转基因作物中提取抗体变得可行,并解决植物来源药物商业化面临的主要瓶颈之一。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验